Wikisource:WikiProject Open Access/Programmatic import from PubMed Central/Identification of Novel Functional Inhibitors of Acid Sphingomyelinase

Identification of Novel Functional Inhibitors of Acid Sphingomyelinase
Johannes Kornhuber; Markus Muehlbacher; Stefan Trapp; Stefanie Pechmann; Astrid Friedl; Martin Reichel; Christiane Mühle; Lothar Terfloth; Teja W. Groemer; Gudrun M. Spitzer; Klaus R. Liedl; Erich Gulbins; Philipp Tripal, edited by Howard Riezman
PLoS ONE , vol. 6, iss. p.


We describe a hitherto unknown feature for 27 small drug-like molecules, namely functional inhibition of acid sphingomyelinase (ASM). These entities named FIASMAs (Functional Inhibitors of Acid SphingoMyelinAse), therefore, can be potentially used to treat diseases associated with enhanced activity of ASM, such as Alzheimer's disease, major depression, radiation- and chemotherapy-induced apoptosis and endotoxic shock syndrome. Residual activity of ASM measured in the presence of 10 µM drug concentration shows a bimodal distribution; thus the tested drugs can be classified into two groups with lower and higher inhibitory activity. All FIASMAs share distinct physicochemical properties in showing lipophilic and weakly basic properties. Hierarchical clustering of Tanimoto coefficients revealed that FIASMAs occur among drugs of various chemical scaffolds. Moreover, FIASMAs more frequently violate Lipinski's Rule-of-Five than compounds without effect on ASM. Inhibition of ASM appears to be associated with good permeability across the blood-brain barrier. In the present investigation, we developed a novel structure-property-activity relationship by using a random forest-based binary classification learner. Virtual screening revealed that only six out of 768 (0.78%) compounds of natural products functionally inhibit ASM, whereas this inhibitory activity occurs in 135 out of 2028 (6.66%) drugs licensed for medical use in humans.


Acid sphingomyelinase (ASM, EC is a lysosomal glycoprotein that catalyses the hydrolysis of sphingomyelin into ceramide and phosphorylcholine. Fusion of secretory lysosomes with the cell surface and translocation of lysosomal ASM onto the outer leaflet of the cell membrane plays an important role during stress response [1]. CD95 ligands and cytokines such as tumor necrosis factor-α, interleukin-1 and interferon-γ but also other stimuli including oxidative stress, reactive oxygen and nitrogen species, ionizing radiation, UV-C radiation, heat shock and other agents of stress, injury or infections by HIV or bacteria have been shown to stimulate ceramide production [2][3], assumed to be in part due to increased ASM activity. Ceramide, in turn, leads to membrane reorganization and downstream signalling that results in cell activation, very often cell stress or apoptosis. In addition to ASM, at least three other sphingomyelinases have been described in mammalian cells that vary in their pH optimum and cofactor dependency. Although these enzymes and an existing de novo synthesis pathway are alternative mechanisms for ceramide generation, activation of ASM itself has been proven to be critical for some cellular responses, such as apoptosis induced by reactive oxygen and nitrogen species [4], chemotherapy drugs such as cisplatin [5], bacteria [6], radiation [7] and CD95 [8]. Furthermore, in contrast to other sphingomyelinases, ASM activity is tightly regulated [9].

Ceramide is further metabolized to sphingosine and sphingosine-1-phosphate by acid ceramidase (AC, EC and sphingosine kinases. While the biological function of sphingosine is largely unknown, sphingosine-1-phosphate has been shown to be involved in cellular differentiation, proliferation and cell migration [10][11]. This dynamic balance between ceramide and sphingosine-1-phosphate is referred to as the “ceramide/sphingosine-1-phosphate rheostat” [12][13], maintaining the balance between growth and cell death.

ASM is best known for its involvement in Niemann-Pick disease, a lysosomal storage disease due to an inherited enzyme deficiency [14]. Pathological reduction of ASM activity may be caused by mutations in the ASM gene itself. The severity of Niemann-Pick disease correlates with the decrease of ASM activity [15]. However, studies using cells derived from Niemann-Pick disease patients or from ASM knock-out mice revealed that the deficiency of this enzyme might also have beneficial consequences, including anti-apoptotic and cytoprotective effcts. In fact, there is increasing evidence that ASM activation and ceramide accumulation play a central role in the development of common human diseases (reviewed in Smith & Schuchman [16]). Reports have been published of aberrant activation of ASM and/or altered levels of ceramide, for instance, for several psychiatric and neurological disorders such as major depression [17][18], morphine antinociceptive tolerance [19], Alzheimer's disease [20][21], spinal cord injury [22] and seizure disorder [23].

Therefore, ASM inhibitors hold promise for a number of new clinical therapies and might be used to prevent apoptosis and other negative effects occurring in different disease states such as in ischemia, stroke, Alzheimer's dementia, Parkinson's disease, Huntington's chorea, and of certain infections, in endotoxemia, and in atherosclerosis, and for the therapy of major depressive disorder [17], [24][25]. Currently, only few examples of inhibitors directly interacting with ASM are known. These substances include physiological inhibitors of ASM such as phosphatidyl-myo-inositol-3,4,5-trisphosphate [26], L-α-phosphatidyl-D-myo-inositol-3,5-bisphosphate [27] and non-natural direct inhibitors of ASM, such as SMA-7 [28] and AD2765 [29]. A high throughput screening for direct ASM inhibitors was unsuccessful in finding lead structures [30]. The rational development of compounds that block ASM by direct interaction with the enzyme is difficult, since the crystal structure of the enzyme is not yet available. On the other hand, it has been known since the 1970s that some weak organic bases have the potential to reduce the activity of ASM [17], [31][32]. It has been suggested that ASM is bound to intra-lysosomal membranes, and thereby protected against its own proteolytic inactivation. Weak bases, such as desipramine 168 (for numbering of compounds see Table S1), strongly accumulate in acidic intracellular compartments like lysosomes [33], [34], a phenomenon called ‘acid trapping’ and in the case of lysosomes ‘lysosomotropism’. This accumulation of desipramine 168 results in detachment of the ASM from the inner lysosomal membrane [35] and its subsequent inactivation, probably by proteolytic degradation [36]. Weak bases, therefore, do not directly inhibit ASM, but result in a functional inhibition of ASM. We have thus proposed the acronym FIASMA for Functional Inhibitor of Acid SphingoMyelinAse [25]. According to this model, functional inhibition of ASM requires high lysosomal concentrations of a weak basic drug.

Previously, we have shown that functional inhibition of ASM is related to high pKa- and high logP-values and have characterized several new FIASMAs, including the antidepressant drugs doxepine 63, fluoxetine 104, maprotilin 109, nortriptyline 114, paroxetine 118 and sertraline 124[37]. The aims of the present study were (1) to identify more FIASMAs, (2) to further improve the in silico prediction of functional ASM inhibition by developing compact and easily-interpretable models with high internal consistency, (3) to investigate the relationship between permeation of the blood-brain barrier and functional inhibition of ASM and (4) to study the distribution of FIASMAs across different classes of drugs licensed for medical use in humans.

Using the present knowledge about lysosomal accumulation and drug-membrane interaction as prerequisite to functional inhibition of ASM, we developed the following hypotheses: FIASMAs (1) have shared structural and physicochemical properties allowing high lysosomal drug concentrations, compatible with partitioning into the inner surface of the lysosomal membrane and alteration of electrostatic membrane properties. We hypothesize that FIASMAs (2) will be found in different therapeutic drug classes and (3) belong to diverse structural drug classes. To reach the lysosome, functional inhibition of ASM requires penetration of drugs through biological membranes, comparable to substances crossing the blood-brain barrier (BBB). We therefore hypothesize (4) that FIASMAs also penetrate the BBB and (5) are therefore overrepresented in drugs active in the central nervous system (CNS).

Results and DiscussionEdit

Identification of novel FIASMAsEdit

We have previously reported functional inhibition of ASM in cell culture for a wide range of compounds at a concentration of 10 µM for 30 min incubation time [37], based on initial experiments with fluoxetine 104. Using a cell-based simulation model, we have meanwhile realized that very high logP- or pKa-values or the presence of two basic nitrogen atoms leads to slow accumulation kinetics [34]. Therefore, we have also tested longer incubation times for such compounds (Table S1) and found lower residual activities of ASM than previously reported for alverine 40, astemizole 43, bepridile 46, camylofine 50, cloperastine 56, dicyclomine 98, drofenine 64, mebeverine 110, mibefradile 74, pimozide 81 and thioridazine 32 (see Table S1). Several of these substances that were measured [37] as not functionally inhibiting ASM (residual activity of ASM above 50% of control value) are actually FIASMAs when prolonged incubation times are used (alverine 40, dicyclomine 98, mebeverine 110, mibefradile 74, pimozide 81). Our results demonstrate that it is important to consider slow lysosomal accumulation kinetics in compounds with very high pKa- and/or very high logP-values and in compounds with two basic nitrogen atoms. In addition to identifying five more of the previously-tested 101 compounds [37] as FIASMAs taking their slower lysosomal accumulation into account (see Table S1: alverine 40, dicyclomine 98, mebeverine 110, mibefradile 74, pimozide 81), we have identified 22 other previously unknown FIASMAs out of our new set of 175 small drug-like compounds (residual activity of ASM of ≤50%: aprindine 141, biperidene 149, carvedilol 160, cepharantine 161, clemastine 170, clofazimine 172, conessine 175, desloratadine 182, dimebon 189, emetine 196, flupenthixol 208, fluphenazine 209, fluvoxamine 210, hydroxyzin 219, loperamide 227, mebhydroline 229, perphenazine 249, profenamine 258, sertindole 277, solasodine 278, tomatidine 291, zolantidine 276). Four of them (dimebon 189: residual ASM activity 44.1%; fluvoxamine 192: residual ASM activity 37.4%; hydroxyzin 219: residual ASM activity 43.0%; mebhydroline 207: residual ASM activity 41.9%) were classified as FIASMAs albeit with less reliability due to experimental error. To the best of our knowledge, functional inhibition of ASM has not previously been described for any of the compounds presented here. Looking at the whole group of FIASMAs which we experimentally investigated (n = 72, Kornhuber et al. 2008 [37] and Table 1), we noticed some general characteristics. These compounds had moderate to high logP-values (ACD10; mean ± SD: 5.45±1.13; range: 2.03–8.89) and possessed at least one basic nitrogen atom responsible for moderate to high pKa-values (ACD10; mean ± SD: 9.04±1.18; range: 4.81–11.20). This qualifies all FIASMAs as cationic amphiphilic drugs. Most FIASMAs had a molecular weight below 500 (ACD10; mean ± SD: 366.3±85.1; range: 263.4–645.3).

Table 1Edit

"Newly-identified FIASMAs.(10.1371/journal.pone.0023852.t001)"
Generic name or substance codeCIDATC codeFDA status [38]
Alverine 403678A03AX08Not listed
Mibefradile 7460663C08CX01Not listed
Pimozide 8116362N05AG02Prescription drug
Dicyclomine 983042A03AA07Prescription drug
Mebeverine 1104031A03AA04Not listed
Aprindine 1412218C01BB04Not listed
Biperidene 1492381N04AA02Prescription drug
Carvedilol 1602585C07AG02Prescription drug
Cepharantine 161360849Not listedNot listed
Clemastine 17026987D04AA14Prescription drug
Clofazimine 1722794J04BA01Prescription drug
Conessine 175441082Not listedNot listed
Desloratadine 182124087R06AX27Prescription drug
Dimebon 189197033Not listedNot listed
Emetine 19610219P01AX02Not listed
Flupenthixol 2085281881N05AF01Not listed
Fluphenazine 2093372N05AB02Prescription drug
Fluvoxamine 2105324346N06AB08Prescription drug
Hydroxyzin 2193658N05BB01Prescription drug
Loperamide 2273955A07DA03Prescription drug
Mebhydroline 22922530R06AX15Not listed
Perphenazine 2494748N05AB03Prescription drug
Profenamine 2583290N04AA05Discontinued drug
Sertindole 27760149N05AE03Not listed
Solasodine 278442985Not listedNot listed
Tomatidine 29165576Not listedNot listed
Zolantidine 30691769Not listedNot listed
See Table S1 for further details and numbering of compounds.CID = PubChem Compound ID.

Functional inhibition of ASM is bimodally distributedEdit

Analysis of the whole set of compounds (n = 276), reveals a bimodal distribution of drugs with respect to functional inhibition of ASM (Figure 1) and a significant deviation from the normal distribution (Kolmogoroff-Smirnov: p<0.001), with the lowest occurrence of FIASMAs at a residual activity between 50 and 60%. Both subpeaks of the bimodal distribution did not significantly deviate from a normal distribution. The reason for the bimodal distribution may be the inevitable presence of physicochemical properties that are non-linearly related to lysosomal drug accumulation and that work in a synergistic way. Since our experimentally-tested compounds were not randomly chosen, a selection bias might also contribute to the bimodal distribution.

Analyzed compounds show a bimodal distribution with respect to functional inhibition of ASM.The histogram includes results of 276 experimentally investigated compounds (see Table S1). The line represents a Gaussian fit to the two peaks.

Random forest learners provide a good binary prediction of functional inhibition of ASMEdit

We divided the dataset into two groups – active compounds (≤50% residual ASM activity, class 1, n = 72) and inactive compounds (>50% residual ASM activity, class 0, n = 204). Usually, dichotomizing continuous variables results in a number of statistical problems, including a loss of statistical power to detect a relation between a variable and outcome [39][40]. In our data, dichotomization is justified by the pronounced bimodal distribution. We performed a qualitative prediction of functional inhibition of ASM using the whole set and random forest learners. The prediction accuracy in the set increased with the number of attributes used. A high precision of prediction was reached with n = 4 attributes, which is only marginally improved by adding a fifth descriptor (Table 2). The successful 4-descriptor combination included logPACD10_logWeight, pKa1_plus_pKa2ACD10mod, pKaMA_ACD10 and si_Weight_vsa_pol. These four descriptors were only moderately correlated to each other (Spearman rank correlation r2 between −0.598 and 0.314, n = 276) and thus provide complementary information. The descriptors logP and pKa have been discussed most frequently in the context of lysosomal accumulation [33], [34]. Intermediate to high logP values have previously been identified as an important precondition for lysosomal accumulation. However, logPACD10_logWeight ( = logPACD10−½ logMW) is more closely related to the diffusion of small molecules through lipid phases than logP itself and has been used to predict BBB permeation [41], [42]. The descriptor pKa1_plus_pKa2ACD10mod represents the sum of the pKa-values of the most basic and the second-most basic nitrogen atoms and thus takes into account the impact of a second basic functional group. The descriptor pKaMA_ACD10 represents the pKa-value of the most acidic group and thus guarantees that acids are correctly classified as being inactive. vsa_pol is an approximation to the sum of van-der-Waals surface areas of polar atoms and has been described to predict BBB permeability [43]. For this descriptor, both hydrogen bond donors and acceptors count as polar atoms. The size-intensive form of the descriptor was chosen here. The four molecular descriptors thus represent electrostatic (pKa1_plus_pKa2ACD10mod, pKaMA_ACD10), hydrophobic (logPACD10_logWeight), polar (vsa_pol) and steric (weight) properties of the molecules. No further steric descriptors were chosen into the model. The reason for this is probably the low variance of steric descriptors as all of the compounds investigated here are small drug-like molecules. The 4-descriptor model presented here is simple, easy to interpret, has high internal consistency and is meaningful in the context of lysosomal accumulation (Table 2). None of the 276 compounds was incorrectly predicted by the 4-descriptor model.

Table 2Edit

"Descriptor combinations were selected by a 200-fold bootstrap-validated Youden-index based on a binary random forest learner using the whole experimental set.(10.1371/journal.pone.0023852.t002)"
Mean 200fold bootstrap-validationFinal model without validation
nDescriptorsYouden-indexMean ± SDAccuracyMean ± SDYouden-indexAccuracy
2logPACD10_logWeight, pKa1_plus_pKa2ACD10mod0.567±0.0900.829±0.0310.9670.989
3logPACD10_logWeight, pKa1_plus_pKa2ACD10mod, pKaMA_ACD100.626±0.0870.852±0.0310.9900.993
4logPACD10_logWeight, pKa1_plus_pKa2ACD10mod, pKaMA_ACD10, si_Weight_vsa_pol0.680±0.0870.884±0.0301.0001.000
5logPACD10_logWeight, pKa1_plus_pKa2ACD10mod, pKaMA_ACD10, si_Weight_vsa_pol, si_Weight_prot_n_PI0.714±0.0860.897±0.0271.0001.000
A 4-descriptor combination provided high internal consistency, which is only marginally improved by addition of a fifth descriptor. Bootstrap-validated performance measures are given as mean ± SD values.

Based on a smaller set of experimentally investigated compounds (n = 101) and a decision tree learner we had previously suggested a 3-descriptor model (logPACD10, pKa1ACD10, k) for qualitative prediction of functional inhibition of ASM [37]. Applying this 3-descriptor model on the large experimental dataset available in the present study (n = 276) still results in a reasonable good prediction of functional inhibition of ASM (mean bootstrap-validated Youden-index: 0.575±0.085, mean bootstrap-validated accuracy 0.831±0.033, Youden-index without bootstrap-validation 1.0, accuracy without bootstrap-validation 1.0). However, the descriptor-combinations presented here (Table 2) outperform the previous prediction system. The previously suggested model [37] was now improved in several ways by using advanced molecular descriptors (e.g. logPACD10−½ logMW instead of logPACD10; pKa1ACD10+pKa2ACD10 instead of pKa1ACD10), by using four instead of three molecular descriptors, by using a random forest learner instead of a simple decision tree learner and by using rigorous model validation. This led to a much more precise prediction system.

Whenever a structure-property-activity relationship (SPAR) model is built, there is a probability that the best model is chance correlation. We therefore performed a response permutation test (also known as Y-scrambling [44][45]). If a strong correlation remains between the selected descriptors and the randomly permutated response, the significance of the proposed model is suspect. The 4-descriptor model (logPACD10_logWeight, pKa1_plus_pKa2ACD10mod, pKaMA_ACD10, si_Weight_vsa_pol) was recalculated for a randomly reordered response. This procedure was performed 1000 times using different random seeds for permutation, resulting in a mean bootstrapping validated Youden-index of 0.001±0.034 and a mean bootstrapping validated accuracy of 0.675±0.014 for the whole experimental set (n = 276). The performance of the 4-descriptor model applied to the original dataset is therefore more than 15 standard deviations above random (mean accuracy in the whole experimental set = 0.884) indicating a large distance between a random response model and a true response model. The whole set comprised 276 compounds, 204 of them in class 0 (inactive) and 72 in class 1 (active). A model assuming all compounds would belong to class 0 (zero rule model) would have an accuracy of 0.739. The accuracy of the chosen model applied to the original dataset is significantly higher than the zero rule model, whereas the model applied to randomly reordered response values has a performance which is even lower than the zero rule model.

The whole process from data pre-processing to model generation and interpretation was in accordance with the OECD/IOMC guidelines for quantitative structure-activity relationship development [46]. This means that our study had (1) a defined endpoint, (2) an unambiguous algorithm, (3) a defined domain of applicability, (4) appropriate measures of goodness-of-fit, robustness and predictivity and (5) a mechanistic interpretation.

Additive effect of FIASMAsEdit

Co-application of structurally diverse FIASMAs results in an additive functional inhibition of ASM, suggesting that these compounds share the same mechanism of inhibition. This is exemplified here by the additive effect of amitriptyline 6 and fluoxetine 104 (Figure 2).

FIASMAs work in an additive way: The combination of a subthreshold-concentration of amitriptyline 6 and fluoxetine 104 (2.5 µM) results in functional inhibition of ASM.This effect is also evident at higher concentrations. Mean values ± SD from 3 experiments are given.

FIASMAs tend to cross the blood-brain barrierEdit

The blood-brain barrier (BBB) is a selective barrier formed by the endothelial cells that line cerebral microvessels [47]. Tight junctions between adjacent endothelial cells force most molecular traffic across the BBB to take the transcellular route [48]. Small lipophilic agents can diffuse freely through the lipid membranes. Most CNS-active drugs use this transcellular lipophilic pathway. Compounds entering the brain have to cross two membrane barriers (both luminal and abluminal plasma membrane) and the cytoplasm of the endothelial cells in brain capillaries. FIASMAs have to go a similar way through the cell to reach the lysosome: they cross two membrane barriers (plasma membrane of the cell, lysosomal membrane) and the cytoplasm. Therefore an analogy between the BBB and the blood-lysosomal barrier can be assumed. For 64 of the 276 compounds investigated here, we found experimental logBB values (logarithmic ratio between the concentration of a compound in brain and blood) in the literature. When residual ASM activity is plotted against logBB values (Figure 3), it is apparent that functional inhibition of ASM (residual activity ≤50%) is found only for compounds that efficiently cross the BBB (logBB≥0).

Functional inhibition of ASM appears to be associated with good passive diffusion across the blood-brain barrier.Experimental logBB values were compiled from the literature, with values greater than 0 indicating good blood-brain barrier permeability. Functional inhibition of ASM was experimentally determined in cell culture; residual ASM activity below 50% relative to control cells indicates active compounds. See also results in Table S1.

FIASMAs violate Lipinski's Rule-of-Five more often than compounds without effect on ASMEdit

We investigated whether or not our experimentally tested compounds (n = 276, Table S1) are in agreement with Lipinski's Rule-of-Five [49]. While 59 of 204 (28.9%) of compounds lacking a significant effect on ASM activity violated the Lipinski's Rule-of-Five, violation occurred in 37 of 72 (51.4%) of FIASMAs (chi-square test, p = 0.001, Table 3). In most of the FIASMAs violation of the Rule-of-Five was due to high lipophilicity. Nevertheless, FIASMAs are orally active and most of them are probably also CNS-active drugs.

Table 3Edit

"FIASMAs frequently violate Lipinski's Rule-of-Five.(10.1371/journal.pone.0023852.t003)"
Experimentally-determined ASM inhibitory activity
FIASMANot acting as FIASMA
Rule-of-Five = 035145
Chi-square-test, p = 0.001.Violation was assumed when there was a contradiction to any of the four rules.Violation of Lipinski's Rule-of-Five was calculated by ACD10 for all compounds with experimentally-determined ASM activity (n = 276).

Virtual screening shows that FIASMAs are enriched in groups of drugs acting at excitable cells but are rare among natural productsEdit

Most of the clinically approved compounds have been developed without specific goals regarding logP- and pKa-values. Therefore, there should be no remarkable differences in these physicochemical properties between groups of drugs approved for medical use. To get a complete picture of the distribution of functional inhibition of ASM within approved drugs, we used the Anatomical Therapeutic Chemical (ATC) drug classification system recommended by the World Health Organization (WHO). Based on the random forest model described above, we analyzed a total of 2440 compounds distributed across 86 third-level drug groups of the ATC codes (with several substances occurring more than once; 2028 different compounds) by a virtual screening approach and found physicochemical characteristics indicative of functional inhibition of ASM in 157 of the 2440 ATC-listed compounds (6.43%). Since some of the drugs in the ATC system are chemically identical, but have a unique ATC-code because of their different clinical indications, a total of 135 of 2028 unique compounds (6.66%) was predicted to functionally inhibit ASM. The distribution of the 157 functional ASM inhibitors across the 86 pharmacologically relevant therapeutic groups significantly deviated from the expected values (Fisher's exact test, p<0.001), but clustered clearly in a few groups. The multiple test correction on Fisher p-values revealed a significant overrepresentation of FIASMAs in only a few therapeutic groups, namely A03 (drugs for functional gastrointestinal disorders), A15 (appetite stimulants), C08 (calcium channel blockers), D04 (antipruritics), N04 (anti-parkinson drugs), N05 (psycholeptics), N06 (psychoanaleptics) and R06 (antihistamines for systemic use). Since group size of the ATC second level drug groups varies strongly, the p-value has a limited explanatory power. From a biological point of view, groups with a high fraction of FIASMAs may be still of interest, even if the p-value is not significant owing to the small size of the group, such as A04 (antiemetics and antinauseants). One common feature of these ATC subgroups with a significant overrepresentation of FIASMAs is the pharmacodynamic involvement of excitable cells where many FIASMAs appear to act primarily. Furthermore, it is evident, that several of the second-level ATC subgroups with a significant number of FIASMAs belong to the CNS active groups (N04, N05, N06).

In contrast to approved drugs for medical use, we found by virtual screening that FIASMAs are rare in natural products. The molecular descriptors necessary for application of the model were calculable in 787 of the 800 “Pure Natural Products” [50]. Two compounds with quaternary nitrogen atoms were excluded. Then we removed 17 duplicates. In six of the remaining 768 compounds (0.78%) the model indicated functional inhibition of ASM. Five of these predicted compounds were also part of the experimental set (Table S1): cepharanthine 161, conessine 175, emetine 196, solasodine 278 and tomatidine 291 and did indeed show functional inhibition of ASM. The rate of predicted FIASMAs in natural products is much lower than the rate of predicted FIASMAs observed in drugs licensed for medical use in humans (6.66%). The applicability domain of our prediction model is small drug-like molecules. The set of Pure Natural Products differs in chemical space from the small drug-like molecules, meaning that these results have to be interpreted with caution.

FIASMAs are structurally heterogeneousEdit

Chemical space and structural diversity are important when comparing different sets of compounds. It is not valid to extend results obtained in one set of compounds to other compound collections without taking into account structural diversity. In order to compare the degree of structural diversity between sets of compounds, we have developed a new and simple measure termed “relative structural diversity” (divrel). This simple measure uses a hierarchical clustering of Tanimoto-coefficients [51] based on 2D-fingerprints (see experimental section) and may be used in addition to more complicated indicators of structural diversity [52]. The divrel of the FIASMAs (n = 72, divrel = 0.667) is somewhat lower but still high compared to the divrel of the whole experimental set (n = 276, divrel = 0.711). For comparison, divrel is similar in the set of ATC compounds investigated (n = 2028, divrel = 0.709) as well as in the set of natural products (n = 768, divrel = 0.747) (Table 4). Thus, the molecular structure of FIASMAs varies widely, as indicated by the high number of clusters. This is supported by the fact that FIASMAs represent different therapeutic classes and different structural classes as evidenced by their ATC-codes (see Table 1). Our results prove that functional inhibition of ASM does not depend on a specific molecular drug class. Instead of specific structural prerequisites, functional inhibition of ASM requires specific physicochemical characteristics of compounds, resulting in high intra-lysosomal concentrations and partitioning of the drug into the inner leaf of the lysosomal membrane.

Table 4Edit

"Comparison of the relative structural diversity of the compound sets investigated here.(10.1371/journal.pone.0023852.t004)"
Whole experimental set2760.711
Pure Natural Products7680.747
Structural diversity was estimated by a new measure called relative structural diversity (divrel, see experimental section). The set of FIASMAs is a subset of the whole experimental set investigated here.

In the current study we used several different compound collections. The experimental set investigated here is showing comparable divrel values to the ATC set. It is therefore appropriate to apply conclusions from the experimental set onto the larger ATC collection. The set of 72 FIASMAs is a subset of the experimental set, which in turn is largely a subset of the ATC drug library. Therefore, these three sets occupy a comparable region of the chemical space, as all these sets are mainly composed of small drug like molecules. The Pure Natural Products cannot easily be compared to the drug-like molecules as their chemicals space differs.

Clinical implications of the findings presented hereEdit

Most of the newly defined FIASMAs described here are included in the WHO drug list of approved and essential medicines [53] and about half of them appear in the US Food and Drug Administration (FDA)-approved drug list [38] (Table 1). These substances not only possess a low toxicity but also a record of a long-term clinical experience – some have been in use for the last five decades. FIASMAs have a number of favourable properties in the context of clinical application [25], suggesting the potential for rapid advancement into preclinical and/or clinical trials. The therapeutic consequences of functional inhibition of ASM are yet poorly understood, however they may induce a number of clinically desired effects. Ceramide and its metabolite sphingosine-1-phosphate have been shown to antagonistically regulate apoptosis, cellular differentiation, proliferation and cell migration. Inhibition of ASM results in anti-apoptotic, proliferative and anti-inflammatory effects. Furthermore, ASM could play a key role in the pathophysiology of depression and in the action of antidepressant drugs [17]. Inhibitors of ASM therefore hold promise for a number of new clinical therapies. Several examples are given here: Induction of stroke by experimental ischemia of the brain was shown to correlate with an activation of the ASM and a release of ceramide [54], [55]. Importantly, ASM-deficient mice were protected from tissue damage caused by focal cerebral ischemia. Furthermore, the ethanol-induced neuronal cell death is mediated, at least in part, by activation of ASM and generation of ceramide [56]. In addition, the lethal gastrointestinal syndrome, which limits the efficacy of radiation and chemotherapy, apparently results from apoptotic damage of the endothelial cells of the microvasculature of the small intestine. Genetic inactivation of ASM prevents this toxicity [57]. Infection induced by the human immunodeficiency virus type I (HIV-1) serves as a further example. HIV-1 induces a dramatic depletion of CD4+ T cells in infected individuals, finally leading to AIDS (acquired immunodeficiency syndrome). The massive loss of CD4 T-lymphocytes is assumed to result from apoptosis, probably due to enhanced sphingomyelin breakdown and accumulation of intracellular ceramide [58]. Interestingly, HIV-1 infected long-term nonprogressors have less elevated lymphocyte-associated ceramide than subjects with evolving AIDS [59], which is paralleled by a lower frequency of apoptotic CD4 and CD8 cells in long-term nonprogressors compared to patients with AIDS [60]. The endotoxic shock syndrome, which is characterized by systemic inflammation, multiple organ damage, circulatory collapse and death, is caused by disseminated endothelial apoptosis sequentially mediated by TNF and ceramide generation [61]. Blocking of this cascade by ASM inhibitors should be preventive and/or therapeutic against the endotoxic shock syndrome. Finally, an imbalance between ASM and acid ceramidase followed by ceramide accumulation has been demonstrated in the hereditary disease cystic fibrosis [62]. In experimental animals, FIASMAs normalize pulmonary ceramide and inflammation [63]. In a clinical pilot study, amitriptyline 6 led to an improved respiratory function in affected patients [64]. Further examples include the treatment of e.g. Alzheimer's disease, major depression, inflammatory bowel disease [28], liver cell death and anaemia occurring in Wilson disease, and pulmonary edema in acute lung injury [65]. Recently, it has been shown that gilenya (FTY720), a drug licensed for treatment of multiple sclerosis, acts as a FIASMA [66]. This novel mechanism of action may explain at least in part the beneficial effects of gilenya in multiple sclerosis.

AC is a lysosomal enzyme degrading ceramide to sphingosine. Cationic amphiphilic agents like desipramine, chlorpromazine and chloroquine have been shown to result in both, a reduced level of AC protein and in an increased level of cellular ceramide [67], [68]. Despite its potential importance, the influence of medically used drugs on AC has not yet been systematically studied. In a cell culture-based pilot study on more than 100 small drug-like compounds (CM, unpublished), FIASMAs had a significantly stronger AC inhibitory effect than non-FIASMAs. However, the effect on AC was less pronounced compared to their effect on ASM as none of the compounds reduced AC activity to levels below 50%. Moreover, because of the considerably lower enzyme activity of the AC compared to ASM (about 25 fold in cell lysates using fluorescently labelled substrates; CM unpublished), the absolute net effect of potentially inhibitory drugs is expected to be dominated by their influence on ASM. The observation of reduced ceramide levels in the mouse hippocampus after application of amitriptyline or fluoxetine (EG, unpublished results) is in agreement with this hypothesis. Nevertheless, the potential dual effect of small drug-like compounds on ASM as well as AC deserves further research with the aim to identify compounds with specific inhibitory activity for therapeutic use.

Strengths and limitations of the studyEdit

Strength: We identified 27 novel FIASMAs, many of them FDA-approved for clinical use in humans. Model construction was based on a large number of experimentally investigated compounds, and used standard Molecular Operating Environment (MOE) descriptors as well as a multitude of novel hypothesis-driven molecular descriptors, like k, n_pdN, CSA and calculated lysosomal drug concentration (Table 5). We did not use 3D-descriptors, which depend on stereoisomers, preprocessing and energy minimization. Furthermore, we made use of size-intensive descriptors. Remarkably, none of the descriptors of the final model was a standard MOE-descriptor. We applied machine learning algorithms with a low proneness to overfitting (random forest) and performed a rigorous model validation (bootstrap). Our performance measure was well suited for dysbalanced bimodal data (Youden-index). We thus developed a simple model with high internal consistency, high external predictivity (mean bootstrapped accuracy of about 87% in the experimental set), and with a mechanistic interpretation. Finally, we introduce a new measure for comparison of structural heterogeneity between sets of compounds (divrel).

Table 5Edit

"List of programmed and calculated descriptors that were used in addition to the standard MOE-descriptors.(10.1371/journal.pone.0023852.t005)"
Name of the descriptorDescription
AALength of the amphiphilic axis [69]
CSACross-sectional area [69]
NOOMNumber of atoms outside the amphiphilic axis [69]
LiLongest distance from an ionized atom to another atom [69]
MpcLongest distance from the atom with the highest partial charge [69]
n_qNNumber of quaternary nitrogen atoms
n_COOHNumber of carboxylic acid functions [70]
n_OpNSum of nitrogen and oxygen atoms [71]
n_halNumber of halogen atoms (based on: Norinder and Haeberlein [71])
n_XpCSum of halogen and carbon atoms (based on: Norinder and Haeberlein [71])
n_ionNumber of ionized atoms (based on: Lanevskij et al. [41])
n_PINumber of positive ionizable groups (based on: Lanevskij et al. [41])
n_pdNNumber of protonized delocalized nitrogen atoms in the N-C = N motif
n_pHNumber of polar hydrogen atoms [72]
n_polNumber of polar atoms [72]
n_aminesNumber of amines
n_pNnumber of protonated nitrogen atoms at pH 7
I3+1 for amines, −1 for acids, otherwise 0 [73]
QMAXnegHighest negative partial charge [70]
QMAXposHighest positive partial charge [70]
QMEANNAverage partial charge in nitrogen atoms
QSUMHSum of all partial charges on hydrogen atoms
QSUMOSum of all partial charges on oxygen atoms [70]
QMINNLowest partial charge on nitrogen atoms
QSUMNSum of all partial charges on nitrogen atoms
QaminesAverage partial charge on amines
CLysCalculated lysosomal concentration [34]
LALipoaffinity [74]
logPACD10_minus_O_NLogP – number of oxygen and nitrogen atoms [71]
logPACD10_logWeightlogPACD10−½*logWeight [41], [42]
pKa1_plus_pKa2ACD10modif pKa2ACD10>0: pKa1ACD10 + pKa2ACD10, else: pKa1ACD10
si_Weight-DescriptorsSize-intensive descriptors [75] using molecular weight as divisor

Limitations: The chemoinformatic model presented here is valid for small drug-like molecules only. The model allows the qualitative prediction only. The effect of a substance on ASM activity under therapeutic conditions in vivo depends on the interplay between compound-, treatment- (such as dose and application route) and organism-related variables. Future studies should clarify whether or not functional inhibition of ASM occurs at therapeutic concentrations of the drugs investigated here.


Functional inhibitors of ASM (FIASMAs) are an important class of drugs with newly emerging broad clinical applications. In the present study we have identified 27 novel FIASMAs. Based on a large set of experimental data, we have developed a chemoinformatic model for the accurate prediction of functional inhibition of ASM. Furthermore, we describe important properties of FIASMAs, such as BBB permeability.

Materials and MethodsEdit

Set of compoundsEdit

In addition to the set of 101 compounds previously experimentally investigated with regard to functional inhibition of ASM [37], we selected 175 small organic, drug-like compounds or natural products. The selection aimed at obtaining compounds with high structural diversity, with diversity regarding strength and number of acidic and basic functional groups, and diversity regarding logP values. Basic lipophilic compounds were overrepresented in order to obtain a sufficient number of FIASMAs and in order to avoid a greatly unbalanced class distribution for classification tasks. Of the total set of 276 compounds (Table S1) with a mean molecular weight of 359.9 (88.2–847.0), 23 were acids with a most acidic pKa-value as estimated by ACD10 [76] below 10 and no relevant basic group (“acid”) and 155 were weak bases with a most basic pKa-value≥3 and neither another relevant basic nor any relevant acidic group (“monobase”). Further 22 compounds possessed both a basic nitrogen atom with a pKa-value≥3 and an acidic group with a pKa-value below 10 (“zwitter”). Additional 45 compounds contained two basic nitrogen atoms both with pKa-values≥3 and no relevant acidic group (“bibase”). The remaining 31 compounds either had no ionisable functional group at all (n = 9) or had pKa-values outside the biologically relevant range (n = 22).

Structure entryEdit

Molecular structures were obtained from the PubChem-Project page [77], [78] (Table S1).


Aclacinomycin-A 133, acrivastine 134, amorolfine 139, clonidine 173, lynestrenol 228, montelukast 239 and rolipram 271 were purchased from Biotrend Chemikalien (Köln, Germany); phenylmethylsulfonyl fluoride 253 and S-methylisothiourea 274 from Calbiochem (Merck, Darmstadt, Germany); allylestrenol 135, atovaquone 142, barnidipine 146, butenafine 155, cepharanthine 161, chlorquinaldol 166, clemastine 170, dienestrol 187, dutasteride 195, nelfinavir 243, solasodine 278 and vinblastine 299 from Chemos (Regenstauf, Germany) and dimebon 189 from Aurora Feinchemie (Graz, Austria). Apomorphin 140, doxorubicin 193, phenserine 251, pranlukast 257, raloxifene 266 and zolantidine (SKB41) 306 were obtained from Tocris (Bristol, UK) and aprindine 141, biperidene 149, buclicine 152, buspiron 154, diosmin 190, emetine 196, encainide 197, fosinopril 211, hydroxyzin 219, ropinirole 272, thiocarlide 287, tiagabine 288 and zafirlukast 305 from VWR (Darmstadt, Germany). Quetiapine 264 was a gift of AstraZeneca (Wedel, Germany). All other substances investigated experimentally were obtained from Sigma-Aldrich (Munich, Germany). All compounds were used in the highest purity available.

Cell cultureEdit

Human brain neuroglioma H4-cells were purchased from Promochem (Wesel, Germany). H4-cells were cultured as described previously [37]. Only cells tested negative for mycoplasma infection were used in the experiments.

Kinetics of lysosomal accumulationEdit

Usually, 30 min of incubation of H4-cells with the test drug was sufficient to induce functional inhibition of ASM. Due to slow accumulaion kinetics some compounds required a longer incubation time. However, prolonged incubation with some compounds (astemizole 43, mibefradil 74, penfluridol 79, fluoxetine 104, sertindole 249, thioridazine 32) resulted in cell death. We therefore aimed at a minimal but still sufficient incubation time for all compounds, which was estimated using a previously developed numerical single cell model [34]: Accumulation of molecules in the cell by diffusion from the external solution into the cytosol, lysosome and mitochondria was calculated with the Fick-Nernst-Planck-equation. The cell model considers the diffusion of neutral and ionic molecules across biological membranes, dissociation into mono- or bivalent ions, adsorption to lipids, and electrical attraction or repulsion. We used the parameters of the standard model [34] as well as the logP-, most basic and most acidic pKa-values as calculated by ACD10 [76] (Table S1). Four different models (“monoacid”, “monobase”, “bibase” and “zwitter”) implemented in Excel sheets were used for kinetic calculations (model version: July 2009). There was no amphoteric compound in our dataset. In the absence of pKa-values in the relevant regions, the monoacid model was used with a pKa-value of 15.

Experimental determination of ASM activityEdit

The activity of ASM was determined in whole cell lysates, as previously described [79]. We aimed to develop a qualitative (binary) SPAR model. Therefore, we did not determine IC50 values, but we determined whether or not a compound acts as functional inhibitor of ASM. Thus, we used a single high concentration of a compound and a sufficient incubation time, which depends on the pharmacokinetic properties of the compound. After the substance was added to the growth medium at a final concentration of 10 µM, cells were kept at 37°C in a humidified atmosphere at 8.5% CO2 for 30 minutes (DMEM: pH 7.5). Compounds with predicted slow lysosomal accumulation kinetics [34] were also investigated at longer incubation times (Table S1). Results are given as residual ASM activity (%) normalized to control cells treated with the solvent alone and represent mean values of three independent experiments, each with a standard deviation of approx. 16%. Because of the bimodal distribution of functional inhibition of ASM (see below), a residual ASM activity ≤50.0% in H4-cells was rated as positive.

Statistical analysisEdit

Deviation from normal distribution (two-sided Kolmogoroff-Smirnov) and chi-square statistics were computed using PASW (Version 18, Chicago, Illinois). One-sided Fisher's exact probability test with Benjamini-Hochberg [80] correction for multiple testing was computed using R software (version version 2.7.0) [81].

Computation of molecular descriptorsEdit

Molecular descriptors were calculated by the ACD/LogD Suite, version 10 [76] (the two most basic pKa-values, the most acidic pKa-value, logP-value), by visual inspection of the molecules [number of heavy atoms at the most basic nitrogen atom (k [37])] and by MOE 2009.10 [82]. The lysosomal concentration of each drug was calculated by a previously developed numerical single cell model [34] (see above) and was also used as a molecular descriptor (CLys). It has previously been suggested that the lowest cross-sectional area of a molecule perpendicular to the amphiphilic axis determines the insertion of a molecule into a biomembrane and thereby its passive diffusion across the BBB [83], [84]. The lowest cross-sectional area (CSA, Table 5) of the molecules perpendicular to the amphiphilic axis in the membrane bound conformation and related molecular descriptors were calculated as previously described [69]. A simple division of molecular descriptors by chemical sample size creates size-intensive descriptors which were shown to result in more compact and more stable models [75]. We used molecular weight (MW) to calculate a size-intensive form of every molecular descriptor. Furthermore, we used an MW-based correction of logP-values (logP−½*logWeight [41], [42]). Further information on these descriptors is available in Table 5 and in the literature [44], [85].

Data pre-processingEdit

Data pre-processing was performed using RapidMiner 5.1 [86]. Features with very low variance were eliminated. Missing values for the most basic pKa-values were substituted by 0, missing most acidic pKa-values were substituted by 15, missing values for k were substituted by 12. Otherwise, we used only molecular descriptors that were available for all compounds and thereby obtained a total of 708 molecular descriptors. The presence of irrelevant and redundant attributes may reduce the performance of learners such as decision tree and random forest [87]. Therefore, before applying random forest learners we reduced the dimensionality of the data by applying feature selection methods. We used both a hypothesis-driven and a hypothesis-free feature selection approach [88], [89] to select descriptors with potential relevance. For the hypothesis-free selection, attributes were chosen by at least one of the following methods: wrapper [90], relief [91], [92], correlation based weighting, information gain weighting, standard deviation based weighting, support vector machine based weighting and rule based weighting. We thus ended up with about 100 molecular descriptors used for random forest learners.

Model constructionEdit

Models were generated using machine learning algorithms [93], [94] provided by RapidMiner 5.1 [86]. The whole experimental set was used, since examples are too precious to waste during model generation [95]. A modified beam-search [96] served to identify high-performing single attributes or attribute combinations. Models were validated by bootstrapping (n = 200). Because of the unbalanced class distribution, the Youden-Index [97][98] (sensitivity + specificity−1) was chosen as primary performance measure evaluating models based on two-class learners. We used a random forest learner [99] for binary classification. In contrast to a simple decision tree learner, random forest learners are more resistant against overfitting and result in more stable models, meaning that small changes in the training set do not lead to completely different models [100], [101], and lead to better predictivity on unknown compounds. The parameters used were: ntree = 51 (number of trees to build), nodesize = 1 (size of the terminal node of the trees in a random forest), mtry = log(m)+1 (number of attributes randomly selected at each node, where m = number of attributes available), allowed maximal depth of the trees = 8.

Whenever a structure activity relations (SAR) model is built, there is a probability that the best model is chance correlation. We used the response permutation test, also known as Y-scrambling [44][45], [102] to detect random effects.

Relative structural diversity of the set of compounds usedEdit

In order to estimate the structural diversity of our investigated sets of compounds, we performed a hierarchical clustering based on Tanimoto coefficients [51] for fingerprints based on tagged graph triangles (TGT) [103], [104]. We calculated the number of clusters at 0.85 similarity measured by Tanimoto coefficients and divided it by the total number of compounds in the test set. We term this measure “relative structural diversity” (divrel).

Higher values for divrel indicate higher structural diversity. The values for divrel can vary from just above zero (when there is only one cluster) to 1 (when each compound defines a separate cluster). For our analysis, we have used the structural TGT keys [103], [104] consisting of 2D pharmacophore features with atom types and distances.

Violation of Lipinski's Rule-of-FiveEdit

Lipinski's Rule-of-Five [49] identifies compounds with properties that would likely make them an orally active drug in humans. The set of four rules describes molecular properties important for a drug's pharmacokinetic properties in the human organism, including its absorption, distribution, metabolism, excretion and toxicity (ADME/Tox). Violation of Lipinski's Rule-of-Five was calculated by ACD10 logD Suite. Violation was assumed when there was a contradiction to any of the four rules.

Data on passive diffusion across the blood-brain barrierEdit

The most common value describing permeability across the blood-brain barrier (BBB) is the logBB. It is defined as the logarithmic ratio between the concentration of a compound in brain and blood. LogBB values below zero indicate poor penetration of the BBB. LogBB values were compiled from a number of published papers [43], [105][106].

Distribution of FIASMAs across the therapeutic and structural classes of the ATC systemEdit

The five-level ATC drug classification system [53], [107], [108] was developed in the early 1970s and provides a comprehensive and logical classification system for categorizing pharmaceutical ingredients approved for medical use in humans. While the first level indicates the main anatomical target of the compound, the second level codes for the pharmacologically-relevant therapeutic main group. The third level indicates the pharmacological subgroup and the fourth the chemical subgroup. The fifth level represents the chemical substance, namely the actual drug entity. On the first level, the code comprises 14 anatomical regions ranging from A (Alimentary tract and metabolism) to V (Various). On the second level, the code consists of 86 pharmacologically-relevant therapeutic groups. Molecular structures of the drugs in their corresponding free base/acid forms were obtained from the SuperDrug database [109]. Export was performed in May 2007, based on the 2005 version of the ATC system. Since we analyzed molecular descriptors of defined molecules, our approach excluded drugs which are entire plants, extracts, drug mixtures, colloids, biopolymers, resins, large peptides and inorganic substances like metals and simple salts. Furthermore, we excluded compounds with a quaternary nitrogen atom, as they do not cross biological membranes via passive diffusion [41]. All compounds were analyzed by their appearance in the ATC system, i.e. substances with multiple effects and different therapeutic indications or different enantiomeric forms were found more than once within the system. In order to determine the distribution of drugs across the ATC system, we used the second level of the 2005 version. Uneven distribution of FIASMAs was tested by a contingency table and one-sided Fisher test. Within this contingency table, the multiple test correction (Benjamini-Hochberg [80]) identified therapeutic groups with a significantly enriched fraction of FIASMAs [110].

Distribution of FIASMAs across natural productsEdit

Molecular structures of “Pure Natural Products” were downloaded from MicroSourceDiscovery [50] and analysed using the random forest model based on the whole experimental set. This set of “Pure Natural Products” consisted of 800 alkaloids, flavonoids, sterols/triterpenes, diterpenes/sesquiterpenes, benophenones/chalcones/stilbenes, limonoids/quassinoids and chomones/courmarines, benzofurans/benzopyrans, rotenoids/xanthones, carbohydrates and benztropolones/depsides/depsidones. Compounds with a quaternary nitrogen atom and duplicates were again excluded from this analysis.

Supporting InformationEdit

Table S1Edit

Compounds investigated in this study.(DOC) (data file pone.0023852.s001.doc) We thank Andrea Leicht, Michaela Schäfer and Alice Konrad for excellent technical assistance, Torsten Kuwert (Department for Nuclear Medicine, University Hospital Erlangen) for support with the use of the radionucleotide facility and Elisabeth Naschberger (Division of Molecular and Experimental Surgery, University Hospital Erlangen) for support with quantifying radioactivity. We would like to thank Robert Preissner (Berlin Center of Genome Based Bioinformatics, Charité) for providing molecular structures of compounds contained in the ATC-system by a special export from the SuperDrug databank. Quetiapine 264 was a gift of AstraZeneca (Wedel, Germany). MicroDiscovery (Berlin) calculated the contingency table statistics. Rapid-I GmbH (Dortmund, Germany) implemented new operators and parameters into the RapidMiner software, rendering it suitable for developing SAR models.Competing Interests: LT is employed by a commercial company (Molecular Networks GmbH, Erlangen, Germany). The authors' employment does not alter their adherence to all the PLoS ONE policies on sharing data and materials, as detailed online in the guide for authors.Funding: The work was supported in part by a grant from the DFG (KO 947/11-1, GU 335/23-1). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding received for this study.


  1. Jin, S; Yi, F; Zhang, F; Poklis, JL & Li, PL (2008), “Lysosomal targeting and trafficking of acid sphingomyelinase to lipid raft platforms in coronary endothelial cells.”, Arterioscler Thromb Vasc Biol 28: 2056–2062, 18772496, pmid:18772496 
  2. Hannun, YA & Luberto, C (2000), “Ceramide in the eukaryotic stress response.”, Trends Cell Biol 10: 73–80, 10652518, pmid:10652518 
  3. Chung, HS; Park, SR; Choi, EK; Park, HJ & Griffin, RJ (2003), “Role of sphingomyelin-MAPKs pathway in heat-induced apoptosis.”, Exp Mol Med 35: 181–188, 12858017, pmid:12858017 
  4. Castillo, SS; Levy, M; Thaikoottathil, JV & Goldkorn, T (2007), “Reactive nitrogen and oxygen species activate different sphingomyelinases to induce apoptosis in airway epithelial cells.”, Exp Cell Res 313: 2680–2686, 17498692, pmid:17498692 
  5. Rebillard, A; Rioux-Leclercq, N; Muller, C; Bellaud, P & Jouan, F (2008), “Acid sphingomyelinase deficiency protects from cisplatin-induced gastrointestinal damage.”, Oncogene 27: 6590–6595, 18679423, pmid:18679423 
  6. Grassmé, H; Jendrossek, V; Riehle, A; von Kürthy, G & Berger, J (2003), “Host defense against Pseudomonas aeruginosa requires ceramide-rich membrane rafts.”, Nat Med 9: 322–330, 12563314, pmid:12563314 
  7. Santana, P; Peña, LA; Haimovitz-Friedman, A; Martin, S & Green, D (1996), “Acid sphingomyelinase-deficient human lymphoblasts and mice are defective in radiation-induced apoptosis.”, Cell 86: 189–199, 8706124, pmid:8706124 
  8. Kirschnek, S; Paris, F; Weller, M; Grassmé, H & Ferlinz, K (2000), “CD95-mediated apoptosis in vivo involves acid sphingomyelinase.”, J Biol Chem 275: 27316–27323, 10867001, pmid:10867001 
  9. Jenkins, RW; Canals, D & Hannun, YA (2009), “Roles and regulation of secretory and lysosomal acid sphingomyelinase.”, Cell Signal 21: 836–846, 19385042, pmid:19385042 
  10. Schwarz, A & Futerman, AH (1997), “Distinct roles for ceramide and glucosylceramide at different stages of neuronal growth.”, J Neurosci 17: 2929–2938, 9096129, pmid:9096129 
  11. Toman, RE; Payne, SG; Watterson, KR; Maceyka, M & Lee, NH (2004), “Differential transactivation of sphingosine-1-phosphate receptors modulates NGF-induced neurite extension.”, J Cell Biol 166: 381–392, 15289497, pmid:15289497 
  12. Spiegel, S & Merrill, AH (1996), “Sphingolipid metabolism and cell growth regulation.”, FASEB J 10: 1388–1397, 8903509, pmid:8903509 
  13. Spiegel, S; Cuvillier, O; Edsall, LC; Kohama, T & Menzeleev, R (1998), “Sphingosine-1-phosphate in cell growth and cell death.”, Ann N Y Acad Sci 845: 11–18, 9668339, pmid:9668339 
  14. Brady, RO; Kanfer, JN; Mock, MB & Fredrickson, DS (1966), “The metabolism of sphingomyelin. II. Evidence of an enzymatic deficiency in Niemann-Pick disease.”, Proc Natl Acad Sci U S A 55: 366–369, 5220952, pmid:5220952 
  15. Schuchman, EH & Miranda, SRP (1997), “Niemann-Pick disease: Mutation update, genotype/phenotype correlations, and prospects for genetic testing.”, Genet Test 1: 13–19, 10464620, pmid:10464620 
  16. Smith, EL & Schuchman, EH (2008), “The unexpected role of acid sphingomyelinase in cell death and the pathophysiology of common diseases.”, FASEB J 22: 3419–3431, 18567738, pmid:18567738 
  17. 17.0 17.1 17.2 17.3 Kornhuber, J; Medlin, A; Bleich, S; Jendrossek, V & Henkel, AW (2005), “High activity of acid sphingomyelinase in major depression.”, J Neural Transm 112: 1583–1590, 16245071, pmid:16245071 
  18. Kornhuber, J; Reichel, M; Tripal, P; Groemer, TW & Henkel, AW (2009), “The role of ceramide in major depressive disorder.”, Eur Arch Psychiatry Clin Neurosci 259: S199–S204, 19876679, pmid:19876679 
  19. Ndengele, MN; Cuzzocrea, S; Masini, E; Vinci, MC & Esposito, E (2009), “Spinal ceramide modulates the development of morphine antinociceptive tolerance via peroxynitrite-mediated nitroxidative stress and neuroimmune activation.”, J Pharmacol Exp Ther 329: 64–75, 19033555, pmid:19033555 
  20. Malaplate-Armand, C; Florent-Béchard, S; Youssef, I; Koziel, V & Sponne, I (2006), “Soluble oligomers of amyloid-β peptide induce neuronal apoptosis by activating a cPLA2-dependent sphingomyelinase-ceramide pathway.”, Neurobiol Dis 23: 178–189, 16626961, pmid:16626961 
  21. Han, X; Holtzman, M; McKeel, DW; Kelley, J & Morris, JC (2002), “Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer's disease: potential role in disease pathogenesis.”, J Neurochem 82: 809–818, 12358786, pmid:12358786 
  22. Cuzzocrea, S; Deigner, H-P; Genovese, T; Mazzon, E & Esposito, E (2009), “Inhibition of ceramide biosynthesis ameliorates pathological consequences of spinal cord injury.”, Shock 31: 634–644, 18838947, pmid:18838947 
  23. Mikati, MA; Zeinieh, M; Habib, RA; El, HJ & Rahmeh, A (2008), “Changes in sphingomyelinases, ceramide, Bax, Bcl2, and caspase-3 during and after experimental status epilepticus.”, Epilepsy Res 81: 161–166, 18603412, pmid:18603412 
  24. Kolesnick, R (2002), “The therapeutic potential of modulating the ceramide/sphingomyelin pathway.”, J Clin Invest 110: 3–8, 12093880, pmid:12093880 
  25. 25.0 25.1 25.2 Kornhuber, J; Tripal, P; Reichel, M; Mühle, C & Rhein, C (2010), “Functional inhibitors of acid sphingomyelinase (FIASMAs): a novel pharmacological group of drugs with broad clinical applications.”, Cell Physiol Biochem 26: 9–20, 20502000, pmid:20502000 
  26. Testai, FD; Landek, MA; Goswami, R; Ahmed, M & Dawson, G (2004), “Acid sphingomyelinase and inhibition by phosphate ion: role of inhibition by phosphatidyl-myo-inositol 3,4,5-triphosphate in oligodendrocyte cell signaling.”, J Neurochem 89: 636–644, 15086520, pmid:15086520 
  27. Kölzer, M; Arenz, C; Ferlinz, K; Werth, N & Schulze, H (2003), “Phosphatidylinositol-3,5-bisphosphate is a potent and selective inhibitor of acid sphingomyelinase.”, Biol Chem 384: 1293–1298, 14515991, pmid:14515991 
  28. 28.0 28.1 Sakata, A; Ochiai, T; Shimeno, H; Hikishima, S & Yokomatsu, T (2007), “Acid sphingomyelinase inhibition suppresses lipopolysaccharide-mediated release of inflammatory cytokines from macrophages and protects against disease pathology in dextran sulphate sodium-induced colitis in mice.”, Immunology 122: 54–64, 17451462, pmid:17451462 
  29. Darroch, PI; Dagan, A; Granot, T; He, X & Gatt, S (2005), “A lipid analogue that inhibits sphingomyelin hydrolysis and synthesis, increases ceramide, and leads to cell death.”, J Lipid Res 46: 2315–2324, 16150832, pmid:16150832 
  30. Mintzer, RJ; Appell, KC; Cole, A; Johns, A & Pagila, R (2005), “A novel high-throughput screening format to identify inhibitors of secreted acid sphingomyelinase.”, J Biomol Screen 10: 225–234, 15809318, pmid:15809318 
  31. Albouz, S; Hauw, JJ; Berwald-Netter, Y; Boutry, JM & Bourdon, R (1981), “Tricyclic antidepressants induce sphingomyelinase deficiency in fibroblast and neuroblastoma cell cultures.”, Biomedicine 35: 218–220, 6285997, pmid:6285997 
  32. Sakuragawa, N; Sakuragawa, M; Kuwabara, T; Pentchev, PG & Barranger, JA (1977), “Niemann-Pick disease experimental model: sphingomyelinase reduction induced by AY-9944.”, Science 196: 317–319, 66749, pmid:66749 
  33. 33.0 33.1 de Duve, C; de Barsy, T; Poole, B; Trouet, A & Tulkens, P (1974), “Lysosomotropic agents.”, Biochem Pharmacol 23: 2495–2531, 4606365, pmid:4606365 
  34. 34.0 34.1 34.2 34.3 34.4 34.5 34.6 34.7 Trapp, S; Rosania, GR; Horobin, RW & Kornhuber, J (2008), “Quantitative modeling of selective lysosomal targeting for drug design.”, Eur Biophys J 37: 1317–1328, 18504571, pmid:18504571 
  35. Kölzer, M; Werth, N & Sandhoff, K (2004), “Interactions of acid sphingomyelinase and lipid bilayers in the presence of the tricyclic antidepressant desipramine.”, FEBS Lett 559: 96–98, 14960314, pmid:14960314 
  36. Hurwitz, R; Ferlinz, K & Sandhoff, K (1994), “The tricyclic antidepressants desipramine causes proteolytic degradation of lysosomal sphingomyelinase in human fibroblasts.”, Biol Chem Hoppe Seyler 375: 447–450, 7945993, pmid:7945993 
  37. 37.0 37.1 37.2 37.3 37.4 37.5 37.6 37.7 37.8 37.9 Kornhuber, J; Tripal, P; Reichel, M; Terfloth, L & Bleich, S (2008), “Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.”, J Med Chem 51: 219–237, 18027916, pmid:18027916 
  38. 38.0 38.1 Approved Drug Products with Therapeutic Equivalence Evaluations, U.S. Department of Health and Human Servies. Food and Drug Administration. Center for Drug Evaluation and Research. Office of Pharmaceutical Science. Office of Generic Drugs [Anonymous], 2007 
  39. Altman, DG & Royston, P (2006), “The cost of dichotomising continuous variables.”, BMJ 332: 1080, 16675816, pmid:16675816 
  40. Ragland, DR (1992), “Dichotomizing continuous outcome variables: Dependence of the magnitude of association and statistical power on the cutpoint.”, Epidemiology 3: 434–440, 1391136, pmid:1391136 
  41. 41.0 41.1 41.2 41.3 41.4 41.5 Lanevskij, K; Japertas, P; Didziapetris, R & Petrauskas, A (2009), “Ionization-specific prediction of blood-brain permeability.”, J Pharm Sci 98: 122–134, 18481317, pmid:18481317 
  42. 42.0 42.1 42.2 Levin, VA (1980), “Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability.”, J Med Chem 23: 682–684, 7392035, pmid:7392035 
  43. 43.0 43.1 Zhang, L; Zhu, H; Oprea, TI; Golbraikh, A & Tropsha, A (2008), “QSAR modeling of the blood-brain barrier permeability for diverse organic compounds.”, Pharm Res 25: 1902–1914, 18553217, pmid:18553217 
  44. 44.0 44.1 44.2 Todeschini, R & Consonni, V (2000), Handbook of Molecular Descriptors, Weinheim, Germany: Wiley-VCH 
  45. 45.0 45.1 von der Voet, H (1994), “Comparing the predictive accuracy of models using a simple randomization test.”, Chemom Intell Lab Syst 25: 313–323 
  46. Guidance document on the validation of (quantitative) structure-activity relationship [(Q)SAR] modelds., vol. No. 69, 2007, pp. 1–154 [Anonymous]OECD: Organisation for economic co-operation and development. IOMC: Inter-organization programme for the sound management of chemicals 
  47. Bradbury, MW (1993), “The blood-brain barrier.”, Exp Physiol 78: 453–472, 8398100, pmid:8398100 
  48. Cecchelli, R; Berezowski, V; Lundquist, S; Culot, M & Renftel, M (2007), “Modelling of the blood-brain barrier in drug discovery and development.”, Nat Rev Drug Discov 6: 650–661, 17667956, pmid:17667956 
  49. 49.0 49.1 Lipinski, CA; Lombardo, F; Dominy, BW & Feeney, PJ (1997), “Experimental and computational approaches to estimate solubility and permeability in drug discovery and developmental settings.”, Adv Drug Deliv Rev 23: 3–25 
  50. 50.0 50.1 Micro Source Discovery Pure Natural Products. Available: Accessed: 2011 Aug 12 
  51. 51.0 51.1 Willett, P (2006), “Similarity-based virtual screening using 2D fingerprints.”, Drug Discov Today 11: 1046–1053, 17129822, pmid:17129822 
  52. Akella, LB & Decaprio, D (2010), “Cheminformatics approaches to analyze diversity in compound screening libraries.”, Curr Opin Chem Biol 14: 325–330, 20457001, pmid:20457001 
  53. 53.0 53.1 The WHO Collaborating Centre for Drug Statistics Methodology, Norwegian Institute of Public Health The ATC/DDD System. Available: Accessed: 2011 Aug 12 
  54. Yu, ZF; Nikolova-Karakashian, M; Zhou, D; Cheng, G & Schuchman, EH (2000), “Pivotal role for acidic sphingomyelinase in cerebral ischemia-induced ceramide and cytokine production, and neuronal apoptosis.”, J Mol Neurosci 15: 85–97, 11220788, pmid:11220788 
  55. Altura, BM; Gebrewold, A; Zheng, T & Altura, BT (2002), “Sphingomyelinase and ceramide analogs induce vasoconstriction and leukocyte-endothelial interactions in cerebral venules in the intact rat brain: Insight into mechanisms and possible relation to brain injury and stroke.”, Brain Res Bull 58: 271–278, 12128152, pmid:12128152 
  56. Pascual, M; Valles, SL; Renau-Piqueras, J & Guerri, C (2003), “Ceramide pathways modulate ethanol-induced cell death in astrocytes.”, J Neurochem 87: 1535–1545, 14713309, pmid:14713309 
  57. Paris, F; Fuks, Z; Kang, A; Capodieci, P & Juan, G (2001), “Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice.”, Science 293: 293–297, 11452123, pmid:11452123 
  58. Van Veldhoven, PP; Matthews, TJ; Bolognesi, DP & Bell, RM (1992), “Changes in bioactive lipids, alkylacylglycerol and ceramide, occur in HIV-infected cells.”, Biochem Biophys Res Commun 187: 209–216, 1520301, pmid:1520301 
  59. De Simone, C; Cifone, GM; Roncaioli, P; Moretti, S & Famularo, G (1996), “Ceramide, AIDS and long-term survivors.”, Immunol Today 17: 48, 8652055, pmid:8652055 
  60. Pantaleo, G; Menzo, S; Vaccarezza, M; Graziosi, C & Cohen, OJ (1995), “Studies in subjects with long-term nonprogressive human immunodeficiency virus infection.”, N Engl J Med 332: 209–216, 7808486, pmid:7808486 
  61. Haimovitz-Friedman, A; Cordon-Cardo, C; Bayoumy, S; Garzotto, M & McLoughlin, M (1997), “Lipopolysaccharide induces disseminated endothelial apoptosis requiring ceramide generation.”, J Exp Med 186: 1831–1841, 9382882, pmid:9382882 
  62. Teichgräber, V; Ulrich, M; Endlich, N; Riethmüller, J & Wilker, B (2008), “Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis.”, Nat Med 14: 382–391, 18376404, pmid:18376404 
  63. Becker, KA; Riethmüller, J; Lüth, A; Döring, G & Kleuser, B (2010), “Acid sphingomyelinase inhibitors normalize pulmonary ceramide and inflammation in cystic fibrosis.”, Am J Respir Cell Mol Biol 42: 716–724, 19635928, pmid:19635928 
  64. Riethmüller, J; Anthonysamy, J; Serra, E; Schwab, M & Döring, G (2009), “Therapeutic efficacy and safety of amitriptyline in patients with cystic fibrosis.”, Cell Physiol Biochem 24: 65–72, 19590194, pmid:19590194 
  65. Göggel, R; Winoto-Morbach, S; Vielhaber, G; Imai, Y & Lindner, K (2004), “PAF-mediated pulmonary edema: a new role for acid sphingomyelinase and ceramide.”, Nat Med 10: 155–160, 14704790, pmid:14704790 
  66. Dawson, G & Qin, J (2011), “Gilenya (FTY720) inhibits acid sphingomyelinase by a mechanism similar to tricyclic antidepressants.”, Biochem Biophys Res Commun 404: 321–323, 21130737 doi:10.1016/j.bbrc.2010.11.115, pmid:21130737 
  67. Elojeimy, S; Holman, DH; Liu, X; El-Zawahry, A & Villani, M (2006), “New insights on the use of desipramine as an inhibitor for acid ceramidase.”, FEBS Lett 580: 4751–4756, 16901483, pmid:16901483 
  68. Canals, D; Perry, DM; Jenkins, RW & Hannun, YA (2011), “Drug targeting of sphingolipid metabolism: sphingomyelinases and ceramidases.”, Br J Pharmacol 163: 694–712, 21615386 doi:10.1111/j.1476-5381.2011.01279.x, pmid:21615386 
  69. 69.0 69.1 69.2 69.3 69.4 69.5 Muehlbacher, M; Spitzer, GM; Liedl, KR & Kornhuber, J (2011), Critical analysis of cross-sectional area for blood-brain barrier prediction on a large scale dataset. J Comput-Aided Mol Des, under review; manuscript available on request ( 
  70. 70.0 70.1 70.2 70.3 Andres, C & Hutter, MC (2006), “CNS permeability of drugs predicted by a decision tree.”, QSAR Comb Sci 25: 305–309 
  71. 71.0 71.1 71.2 71.3 Norinder, U & Haeberlein, M (2002), “Computational approaches to the prediction of the blood-brain distribution.”, Adv Drug Deliv Rev 54: 291–313, 11922949, pmid:11922949 
  72. 72.0 72.1 Fu, X-C; Wang, G-P; Shan, H-L; Liang, W-Q & Gao, J-Q (2008), “Predicting blood-brain barrier penetration from molecular weight and number of polar atoms.”, Eur J Pharm Biopharm 70: 462–466, 18632257, pmid:18632257 
  73. Feher, M; Sourial, E & Schmidt, JM (2000), “A simple model for the prediction of blood-brain partitioning.”, Int J Pharm 201: 239–247, 10878329, pmid:10878329 
  74. Liu, R; Sun, H & So, SS (2001), “Development of quantitative structure-property relationship models for early ADME evaluation in drug discovery. 2. Blood-brain barrier penetration.”, J Chem Inf Comput Sci 41: 1623–1632, 11749589, pmid:11749589 
  75. 75.0 75.1 Purvis, GD (2008), “Size-intensive descriptors.”, J Comput Aided Mol Des 22: 461–468, 18357414, pmid:18357414 
  76. 76.0 76.1 76.2 ACD/LogD Suite. Advanced Chemistry Development IncAvailable: Accessed: 2011 Aug 12 
  77. National Center for Biotechnology Information USA PubChem-Project. Available: Accessed: 2011 Aug 12 
  78. Wang, Y; Xiao, J; Suzek, TO; Zhang, J & Wang, J (2009), “PubChem: a public information system for analyzing bioactivities of small molecules.”, Nucleic Acids Res 37: W623–W633, 19498078, pmid:19498078 
  79. Gulbins, E & Kolesnick, R (2000), “Measurement of sphingomyelinase activity.”, Methods Enzymol 322: 382–388, 10914033, pmid:10914033 
  80. 80.0 80.1 Benjamini, Y & Hochberg, Y (1995), “Controlling the false discovery rate: a practical and powerful approach to multiple testing.”, J R Statist Soc B 57: 289–300 
  81. R Development Core Team R Development Core Team. Available: Accessed: 2011 Aug 12 
  82. Molecular Operating Environment. [Anonymous] MOEAvailable: Accessed: 2011 Aug 12 
  83. Gerebtzoff, G & Seelig, A (2006), “In silico prediction of blood-brain barrier permeation using the calculated molecular cross-sectional area as main parameter.”, J Chem Inf Model 46: 2638–2650, 17125204, pmid:17125204 
  84. Fischer, H; Gottschlich, R & Seelig, A (1998), “Blood-brain barrier permeation: Molecular parameters governing passive diffusion.”, J Membr Biol 165: 201–211, 9767674, pmid:9767674 
  85. Meloun, M & Bordovská, S (2007), “Benchmarking and validating algorithms that estimate pKa values of drugs based on their molecular structures.”, Anal Bioanal Chem 389: 1267–1281, 17676314, pmid:17676314 
  86. 86.0 86.1 Mierswa, I; Wurst, M; Klinkenberg, R; Scholz, M & Euler, T (2006), YALE: Rapid prototyping for complex data mining tasks. In: Proceedings of the 12th ACM SIGKDD International Conference on Knowledge Discovery and Data Mining (KDD-06) 
  87. Amaratunga, D; Cabrera, J & Lee, Y-S (2008), “Enriched random forests.”, Bioinformatics 24: 2010–2014, 18650208, pmid:18650208 
  88. Saeys, Y; Inza, I & Larranaga, P (2007), “A review of feature selection techniques in bioinformatics.”, Bioinformatics 23: 2507–2517, 17720704, pmid:17720704 
  89. Guyon, I & Elisseeff, A (2003), “An introduction of variable and feature selection.”, J Machine Learning Res 3: 1157–1182 
  90. Kohavi, R & John, GH (1997), “Wrappers for feature subset selection.”, Artificial Intelligence 97: 273–324 
  91. Kononenko, I (1994), “Estimating attributes: Analysis and extensions of relief.”, Proceedings of the Seventh European Conference on Machine Learning (Springer Verlag): 171–182 
  92. Kira, K & Rendell, L (1992), “The feature selection problem: traditional methods and a new algorithm.”, Proceedings of the Tenth National Conference on Artificial Intelligence (Penlo Park: AAAI Press/The MIT Press): 129–134 
  93. Witten, IH & Frank, E (2005), Data Mining. Practical Machine Learning Tools and Techniques, Amsterdam: Elsevier 
  94. Alpaydin, E (2008), Maschinelles Lernen, München: Oldenbourg Wissenschaftsverlag GmbH 
  95. Roecker, EB (1991), “Prediction error and its estimation for subset-selected models.”, Technometrics 33: 459–468 
  96. Bisiani, R; Shapiro, S & Eckroth, D (1987), “Beam search.”, Encyclopedia of Artificial Intelligence (New York: Wiley & Sons): 56–58 
  97. Youden, WJ (1950), “Index for rating diagnostic tests.”, Cancer 3: 32–35, 15405679, pmid:15405679 
  98. Bush, WS; Edwards, TL; Dudek, SM; McKinney, BA & Ritchie, MD (2008), “Alternative contingency table measures improve the power and detection of multifactor dimensionality reduction.”, BMC Bioinformatics 9: 238, 18485205, pmid:18485205 
  99. Breiman, L (2001), “Random Forests.”, Machine Learning 45: 5–32 
  100. Zhou, ZH & Li, SZ (2009), “Ensemble Learning.”, Encyclopedia of Biometrics (Berlin: Springer): 270–273 
  101. Svetnik, V; Liaw, A; Tong, C; Culberson, JC & Sheridan, RP (2003), “Random forest: A classification and regression tool for compound classification and QSAR modeling.”, J Chem Inf Comput Sci 43: 1947–1958, 14632445, pmid:14632445 
  102. Wold, S; Eriksson, L & van de Waterbeemd, H (1995), “Statistical validation of QSAR results.”, Chemometrics Methods in Molecular Design (Weinheim: VHC): 309–318 
  103. 103.0 103.1 Ewing, T; Baber, JC & Feher, M (2006), “Novel 2D fingerprints for ligand-based virtual screening.”, J Chem Inf Model 46: 2423–2431, 17125184 doi:10.1021/ci060155b, pmid:17125184 
  104. 104.0 104.1 Williams, C (2006), “Reverse fingerprinting, similarity searching by group fusion and fingerprint bit importance.”, Mol Divers 10: 311–332, 17031535 doi:10.1007/s11030-006-9039-z, pmid:17031535 
  105. Narayanan, R & Gunturi, SB (2005), “In silico ADME modelling: Prediction models for blood-brain barrier permeation using a systematic variable selection method.”, Bioorg Med Chem 13: 3017–3028, 15781411, pmid:15781411 
  106. Platts, JA; Abraham, MH; Zhao, YH; Hersey, A & Ijaz, L (2001), “Correlation and prediction of a large blood-brain distribution data set - an LFER study.”, Eur J Med Chem 36: 719–730, 11672881, pmid:11672881 
  107. [The new classification of drugs: the ATC-code now introduced.]”, Ugeskr Laeger 143: 1037–1039, 1981, 7233607 [Anonymous], pmid:7233607 
  108. The selection and use of essential medicines.”, World Health Organ Tech Rep Ser 920: 1–127, 2004, 15382605 [Anonymous], pmid:15382605 
  109. Goede, A; Dunkel, M; Mester, N; Frommel, C & Preissner, R (2005), “SuperDrug: a conformational drug database.”, Bioinformatics 21: 1751–1753, 15691861, pmid:15691861 
  110. Cox, MK & Key, CH (1993), “Post hoc pair-wise comparisons for the chi-square test of homogeneity of proportions.”, Educational and Psychological Measurement 53: 951–962